[Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment].
The antiarrhythmic efficacy of Propafenone (PF) was evaluated in 24 patients with ventricular hyperkinetic arrhythmias by means of 24-hour Holter monitoring. The drug was administered as an acute bolus (450 mg) and, subsequently, in continuous therapy for 7 days at an average dose of 600 mg/day followed by a 5 days wash-out. The results of our study can be summarized as follows: High antiarrhythmic efficacy of the drug and good tolerability: 19 out of 24 patients showed, in continuous therapy, suppression of ventricular tachycardias (VT), reduction greater than or equal to 90% of couples, reduction greater than or equal to 70% of ventricular premature beats (VPBs). High predictivity value of the oral acute test with PF, (91.6%). Occurrence of first degree atrioventricular block in 4 patients (16.5%) and left bundle branch block in 3 patients (12.5%) with chronic treatment.
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002037:Bundle-Branch Block / Q000139:chemically induced; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004562:Electrocardiography; D005260:Female; D006327:Heart Block / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011405:Propafenone; D011427:Propiophenones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D011427:Propiophenones; D011405:Propafenone
II propafenone nelle aritmie ipercinetiche ventricolari. Valutazione mediante ECG dinamico del test orale acuto e della terapia a breve termine.